This approach—rather than that of reserving therapies for later lines, in which the benefit may not be as significant and not all patients remain eligible to receive them—could enable the maximal chance of deriving durable disease control from available therapies for as many patients with ALK-positive advanced NSCLC as possible. The gene discussed is ALK; the disease is non-small cell lung carcinoma.